Correction: Corrigendum: Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization

TLDR

Nanoparticles are widely used for drug delivery, and targeted delivery to cancer cells is attractive, yet ligand‑modified systems lack mechanistic studies on transport, cell interaction, intracellular trafficking, subcellular fate, and toxicity, especially for IL‑13 peptide targeting IL‑13Rα2 on glioma cells. IL‑13 peptide modification of nanoparticles selectively enhances glioma cell uptake, promotes internalization, shifts the endocytic pathway, and increases tumor localization, improving therapeutic potential.

Abstract

Nanoparticles (NPs) were widely used in drugs/probes delivery for improved disease diagnosis and/or treatment. Targeted delivery to cancer cells is a highly attractive application of NPs. However, few studies have been performed on the targeting mechanisms of these ligand-modified delivery systems. Additional studies are needed to understand the transport of nanoparticles in the cancer site, the interactions between nanoparticles and cancer cells, the intracellular trafficking of nanoparticles within the cancer cells and the subcellular destiny and potential toxicity. Interleukin 13 (IL-13) peptide can specifically bind IL-13Rα2, a receptor that is highly expressed on glioma cells but is expressed at low levels on other normal cells. It was shown that the nanoparticels modification with the IL-13 peptide could improve glioma treatment by selectively increasing cellular uptake, facilitating cell internalization, altering the uptake pathway and increasing glioma localization.